Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Skardal, Aleksander ^a   Murphy, Sean V ^a   Devarasetty, Mahesh ^a   Mead, Ivy ^a   Kang, Hyun Wook ^a   Seol, Young Joon ^a   Zhang, Yu Shrike ^b,c,d   Shin, Su Ryon ^b,c,d   Zhao, Liang ^e   Aleman, Julio ^a,b,c,d   Hall, Adam R ^a   Shupe, Thomas D ^a   Kleensang, Andre ^e   Dokmeci, Mehmet R ^b,c,d   Jin Lee, Sang ^a   Jackson, John D ^a   Yoo, James J ^a   Hartung, Thomas ^e,f   Khademhosseini, Ali ^b,c,d,g,h   Soker, Shay ^a   Bishop, Colin E ^a   Atala, Anthony ^a   more..

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d HARVARD UNIVERSITY   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF KONSTANZ   (Germany)

^g Konkuk University   (South Korea)

^h KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

DEVICES; DRUG DEVELOPMENT; DRUG EFFECT; EQUIPMENT DESIGN; HEART; HUMAN; LAB ON A CHIP; LIVER; LUNG; METABOLISM; MICROFLUIDICS; ORGANOID; PROCEDURES; TISSUE MICROARRAY;

DRUG DISCOVERY; EQUIPMENT DESIGN; HEART; HUMANS; LAB-ON-A-CHIP DEVICES; LIVER; LUNG; MICROFLUIDICS; ORGANOIDS; TISSUE ARRAY ANALYSIS;

EID: 85027888827     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-08879-x     Document Type: Article

References (55)

1. Seruga, B., Ocana, A., Amir, E. & Tannock, I. F. Failures in Phase III: Causes and Consequences. Clin Cancer Res 21, 4552-4560, doi:10.1158/1078-0432.CCR-15-0124 (2015).
2. Jamieson, L. E., Harrison, D. J. & Campbell, C. J. Chemical analysis of multicellular tumour spheroids. The Analyst 140, 3910-3920, doi:10.1039/c5an00524h (2015).
3. Sung, J. H. et al. Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure. Experimental biology and medicine 239, 1225-1239, doi:10.1177/1535370214529397 (2014).
4. Kunz-Schughart, L. A., Freyer, J. P., Hofstaedter, F. & Ebner, R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 9, 273-285, doi:10.1177/1087057104265040 (2004).
5. Pasirayi, G. et al. Low cost microfluidic cell culture array using normally closed valves for cytotoxicity assay. Talanta 129, 491-498, doi:10.1016/j.talanta.2014.06.020 (2014).
6. Ho, W. J. et al. Incorporation of multicellular spheroids into 3-D polymeric scaffolds provides an improved tumor model for screening anticancer drugs. Cancer science 101, 2637-2643, doi:10.1111/j.1349-7006.2010.01723.x (2010).
7. Drewitz, M. et al. Towards automated production and drug sensitivity testing using scaffold-free spherical tumor microtissues. Biotechnol J 6, 1488-1496, doi:10.1002/biot.201100290 (2011).
8. Bhushan, A. et al. Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. Stem Cell Res Ther 4(Suppl 1), S16, doi:10.1186/scrt377 (2013).
9. Polini, A. et al. Organs-on-a-chip: a new tool for drug discovery. Expert opinion on drug discovery 9, 335-352, doi:10.1517/1746044 1.2014.886562 (2014).
10. Sakolish, C. M., Esch, M. B., Hickman, J. J., Shuler, M. L. & Mahler, G. J. Modeling Barrier Tissues In Vitro: Methods, Achievements, and Challenges. EBioMedicine 5, 30-39, doi:10.1016/j.ebiom.2016.02.023 (2016).
11. Benam, K. H. et al. Engineered in vitro disease models. Annual review of pathology 10, 195-262, doi:10.1146/annurevpathol-012414-040418 (2015).
12. Skardal, A., Devarasetty, M., Soker, S. & Hall, A. R. In situ patterned micro 3D liver constructs for parallel toxicology testing in a fluidic device. Biofabrication 7, 031001, doi:10.1088/1758-5090/7/3/031001 (2015).
13. Nieskens, T. T. & Wilmer, M. J. Kidney-on-a-chip technology for renal proximal tubule tissue reconstruction. Eur J Pharmacol. doi:10.1016/j.ejphar.2016.07.018 (2016).
14. Lee, H. & Cho, D. W. One-step fabrication of an organ-on-a-chip with spatial heterogeneity using a 3D bioprinting technology. Lab Chip 16, 2618-2625, doi:10.1039/c6lc00450d (2016).
15. Knowlton, S. & Tasoglu, S. A Bioprinted Liver-on-a-Chip for Drug Screening Applications. Trends Biotechnol, doi:10.1016/j. tibtech.2016.05.014 (2016).
16. Schepers, A., Li, C., Chhabra, A., Seney, B. T. & Bhatia, S. Engineering a perfusable 3D human liver platform from iPS cells. Lab Chip 16, 2644-2653, doi:10.1039/c6lc00598e (2016).
17. Wang, Y. I., Abaci, H. E. & Shuler, M. L. Microfluidic blood-brain barrier model provides in vivo-like barrier properties for drug permeability screening. Biotechnol Bioeng, doi:10.1002/bit.26045 (2016).
18. Bergers, L. I. et al. Immune-competent human skin disease models. Drug Discov Today, doi:10.1016/j.drudis.2016.05.008 (2016).
19. Jackson, E. L. & Lu, H. Three-dimensional models for studying development and disease: moving on from organisms to organs-ona-chip and organoids. Integr Biol (Camb) 8, 672-683, doi:10.1039/c6ib00039h (2016).
20. Zheng, F. et al. Organ-on-a-Chip Systems: Microengineering to Biomimic Living Systems. Small 12, 2253-2282, doi:10.1002/smll.201503208 (2016).
21. Atala, A., Bauer, S. B., Soker, S., Yoo, J. J. & Retik, A. B. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 367, 1241-1246, doi:10.1016/S0140-6736(06)68438-9 (2006).
22. Raya-Rivera, A. et al. Tissue-engineered autologous urethras for patients who need reconstruction: an observational study. Lancet 377, 1175-1182, doi:10.1016/S0140-6736(10)62354-9 (2011).
23. Raya-Rivera, A. M. et al. Tissue-engineered autologous vaginal organs in patients: a pilot cohort study. Lancet 384, 329-336, doi:10.1016/S0140-6736(14)60542-0 (2014).
24. Jouin, D. et al. Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. Eur J Pharm Biopharm 63, 347-355, doi:10.1016/j.ejpb.2006.01.014 (2006).
25. Kaneko, T., Kojima, K. & Yasuda, K. An on-chip cardiomyocyte cell network assay for stable drug screening regarding community effect of cell network size. The Analyst 132, 892-898, doi:10.1039/b704961g (2007).
26. Peters, M. F., Scott, C. W., Ochalski, R. & Dragan, Y. P. Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications. Assay Drug Dev Technol 10, 525-532, doi:10.1089/adt.2011.442 (2012).
27. Lin, C., Ballinger, K. R. & Khetani, S. R. The application of engineered liver tissues for novel drug discovery. Expert opinion on drug discovery 10, 519-540, doi:10.1517/17460441.2015.1032241 (2015).
28. Skardal, A., Devarasetty, M., Forsythe, S. D., Atala, A. & Soker, S. A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol Bioeng In press. (2016).
29. Oleaga, C. et al. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep 6, 20030, doi:10.1038/srep20030 (2016).
30. Maschmeyer, I. et al. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip 15, 2688-2699, doi:10.1039/c5lc00392j (2015).
31. Kang, H. W. et al. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nat Biotechnol In Press.
32. Murphy, S. V. & Atala, A. 3D bioprinting of tissues and organs. Nat Biotechnol 32, 773-785, doi:10.1038/nbt.2958 (2014).
33. Skardal, A. & Atala, A. Biomaterials for integration with 3-d bioprinting. Ann Biomed Eng 43, 730-746, doi:10.1007/s10439-014-1207-1 (2015).
34. Skardal, A., Zhang, J. & Prestwich, G. D. Bioprinting vessel-like constructs using hyaluronan hydrogels crosslinked with tetrahedral polyethylene glycol tetracrylates. Biomaterials 31, 6173-6181, doi:10.1016/j.biomaterials.2010.04.045 (2010).
35. Skardal, A., Zhang, J., McCoard, L., Oottamasathien, S. & Prestwich, G. D. Dynamically crosslinked gold nanoparticle - hyaluronan hydrogels. Adv Mater 22, 4736-4740, doi:10.1002/adma.201001436 (2010).
36. Skardal, A. et al. Tissue specific synthetic ECM hydrogels for 3-D in vitro maintenance of hepatocyte function. Biomaterials 33, 4565-4575, doi:10.1016/j.biomaterials.2012.03.034 (2012).
37. Skardal, A. et al. A hydrogel bioink toolkit for mimicking native tissue biochemical and mechanical properties in bioprinted tissue constructs. Acta Biomater 25, 24-34, doi:10.1016/j.actbio.2015.07.030 (2015).
38. Esch, M. B. et al. How multi-organ microdevices can help foster drug development. Adv Drug Deliv Rev 69-70, 158-169, doi:10.1016/j.addr.2013.12.003 (2014).
39. Xia, Y. & Whitesides, G. M. Soft Lithography. Annu Rev Mater Scie 28, 153-184 (1998).
40. Skardal, A. et al. Bioprinting Cellularized Constructs Using a Tissue-specific Hydrogel Bioink. J Vis Exp, doi:10.3791/53606 (2016).
41. Xu, D. & Peltz, G. Can Humanized Mice Predict Drug "Behavior" in Humans? Annu Rev Pharmacol Toxicol 56, 323-338, doi:10.1146/annurev-pharmtox-010715-103644 (2016).
42. Mathur, A. et al. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development. Stem Cell Res Ther 4(Suppl 1), S14, doi:10.1186/scrt375 (2013).
43. Zhang, Y. S. et al. A cost-effective fluorescence mini-microscope for biomedical applications. Lab Chip 15, 3661-3669, doi:10.1039/c5lc00666j (2015).
44. Shin, S. R. et al. Aptamer-Based Microfluidic Electrochemical Biosensor for Monitoring Cell-Secreted Trace Cardiac Biomarkers. Analytical chemistry. doi:10.1021/acs.analchem.6b02028 (2016).
45. Hittinger, M., Schneider-Daum, N. & Lehr, C. M. Cell and tissue-based in vitro models for improving the development of oral inhalation drug products. Eur J Pharm Biopharm. doi:10.1016/j.ejpb.2017.02.019 (2017).
46. Ing, D. J., Zang, J., Dzau, V. J., Webster, K. A. & Bishopric, N. H. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x. Circ Res 84, 21-33 (1999).
47. Jaffre, F. et al. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation 110, 969-974, doi:10.1161/01.CIR.0000139856.20505.57 (2004).
48. Zhu, J. et al. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol 643, 247-253, doi:10.1016/j.ejphar.2010.06.024 (2010).
49. Shen, Y., Qin, J. & Bu, P. Pathways involved in interleukin-1beta-mediated murine cardiomyocyte apoptosis. Tex Heart Inst J 42, 109-116, doi:10.14503/THIJ-14-4254 (2015).
50. Didagelos, M., Boutis, A., Diamantopoulos, N., Sotiriadou, M. & Fotiou, C. Bleomycin cardiotoxicity during chemotherapy for an ovarian germ cell tumor. Hippokratia 17, 187-188 (2013).
51. Schwarzer, S., Eber, B., Greinix, H. & Lind, P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 12, 748-750 (1991).
52. White, D. A., Schwartzberg, L. S., Kris, M. G. & Bosl, G. J. Acute chest pain syndrome during bleomycin infusions. Cancer 59, 1582-1585 (1987).
53. Yoo, J. J. et al. Delivery System. United States of America patent US 2011/0172611 A1 (2011).
54. Zhang, Y. S. et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci USA 114, E2293-E2302, doi:10.1073/pnas.1612906114 (2017).
55. Zhang, Y. S. et al. An efficient bubble trap for continuous removal of gas bubbles from microfluidic devices. Proceedings of microTAS (2014).